Advanced search
Combine gene, variant, phenotype, region and year filters
Every result shows the extracted entities next to the sentences that support them; rows for the searched entities come first.
Transparent by designEvery result links extracted entities to its source sentence and publication identifier.
Knowledge-base search
About your search
PCSK9 and hypertension are reported together in 2 articles.
Gene
PCSK9
- HGNC
- HGNC:20001
66articles
66mentions
9variants with confirmed gene link
Most co-reported phenotypes (articles)
familial hypercholesterolemia 25dyslipidemia 10diabetes mellitus 7myocardial infarction 7coronary artery disease 4stroke 3hypertension 2obesity 2
Reported variants (articles · ClinVar status)
Phenotype
Hypertension
828articles
828mentions
12co-reported genes shown
Most co-reported genes (articles)
Counts are literature co-mentions in SaudiVarKB, not clinical or causal assertions. Gene details: HGNC; variant status: ClinVar via dbSNP.
Publications
2 records shown · first 60Lipid-Lowering Therapy in Post-Acute Coronary Syndrome Patients: An Observational Study.
PMID 40370629 | PMCID PMC12074677 | DOI 10.14740/cr2063 · Cardiology research · 2025 · 3 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | PCSK9 | “These findings underscore the need for structured follow-up, treatment intensification, and broader use of advanced therapies such as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors to close the real-world treatment gap.” | 0.98 | hgnc_dict_v1 |
| phenotype | hypertension | “RESULTS: A total of 122 patients were included (mean age 63.5 years; 59.8% had both diabetes and hypertension).” | 0.98 | phenotype_alias_lexicon_v2 |
| phenotype | diabetes mellitus | “RESULTS: A total of 122 patients were included (mean age 63.5 years; 59.8% had both diabetes and hypertension).” | 0.93 | phenotype_alias_lexicon_v2 |
Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia.
PMID 30734207 | PMCID PMC6433806 | DOI 10.1007/s10557-019-06852-6 · Cardiovascular drugs and therapy · 2019 · 4 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | PCSK9 | “PURPOSE: This post-hoc analysis examined whether age modified the efficacy and safety of alirocumab, a PCSK9 inhibitor, in patients with heterozygous familial hypercholesterolemia (HeFH), using pooled data from four 78-week placebo-controlled phase 3 trials (ODYSSEY FH I, FH II, LONG TERM, and HIGH FH).” | 0.98 | hgnc_dict_v1 |
| phenotype | hypertension | “RESULTS: Baseline characteristics were similar between treatment groups across all age groups; the proportion of males decreased whereas the proportion of patients with coronary heart disease, diabetes, hypertension, and declining renal function increased with increasing age.” | 0.98 | phenotype_alias_lexicon_v2 |
| phenotype | familial hypercholesterolemia | “Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia.” | 0.98 | phenotype_alias_lexicon_v2 |
| phenotype | diabetes mellitus | “RESULTS: Baseline characteristics were similar between treatment groups across all age groups; the proportion of males decreased whereas the proportion of patients with coronary heart disease, diabetes, hypertension, and declining renal function increased with increasing age.” | 0.93 | phenotype_alias_lexicon_v2 |